Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vandetanib

FDA-approved product (tablet, oral), marketed as Caprelsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vandetanib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Papillary thyroid carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vandetanib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vandetanib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

    NCT00507091 · start 2005-08

    Registered record
    Registry ID
    NCT00507091
    Conditions
    Metastatic; Colorectal; Adenocarcinoma
    Interventions
    ZD6474 (vandetanib) 100mg; Irinotecan; 5-Fluorouracil; Leucovorin; ZD6474 (vandetanib) 300mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-08
    Completion
    2008-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic; Colorectal; Adenocarcinoma
    InterventionZD6474 (vandetanib) 100mg; Irinotecan; 5-Fluorouracil; Leucovorin +1 more
    PhasePhase 1
    Registry statusCompleted

  • ZD6474(Vandetanib) + Alimta Combo Study

    NCT00506051 · start 2005-07

    Registered record
    Registry ID
    NCT00506051
    Conditions
    Carcinoma; Non-Small Cell Lung; Lung Cancer
    Interventions
    ZD6474 (vandetanib) 100mg; pemetrexed; ZD6474 (vandetanib) 300mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2011-10
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma; Non-Small Cell Lung; Lung Cancer
    InterventionZD6474 (vandetanib) 100mg; pemetrexed; ZD6474 (vandetanib) 300mg
    PhasePhase 1
    Registry statusCompleted

  • This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

    NCT00059722 · start 2003-05

    Registered record
    Registry ID
    NCT00059722
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    ZD6474; Placebo; ZD1839
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    2007-06
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionZD6474; Placebo; ZD1839
    PhasePhase 2
    Registry statusCompleted

  • ZD6474 in Treating Patients With Small Cell Lung Cancer

    NCT00066313 · start 2003-05

    Registered record
    Registry ID
    NCT00066313
    Conditions
    Lung Cancer
    Interventions
    vandetanib; adjuvant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    2006-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionvandetanib; adjuvant therapy
    PhasePhase 2
    Registry statusCompleted

  • This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

    NCT00034918 · start 2002-05

    Registered record
    Registry ID
    NCT00034918
    Conditions
    Breast Neoplasms; Metastases, Neoplasm
    Interventions
    ZD6474
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-05
    Completion
    2003-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Metastases, Neoplasm
    InterventionZD6474
    PhasePhase 2
    Registry statusCompleted